Pain affects 100 million Americans

According to the Medical Expenditure Panel Survey (MEPS), approximately 100 million adults in the United States live with chronic pain.

Opioids are still the most effective treatment for most severe/ chronic pain states, but they are hampered by side effects, abuse and addiction.

In addition, many patients cannot tolerate opioids, and that’s where Sana comes in.


Opioid abuse and addiction is now the number 1 health crisis in America. 

The Journal of Pain estimates persistent pain to cost from $560 to $635 billion annually, far exceeding the price of other costly diagnoses such as cardiovascular disease, injury and cancer.

Sana believes that the development of non-invasive bio-therapeutics has the potential to change the clinical management of chronic pain and dramatically reduce health care costs.

The potential to reduce or eliminate pain, at the touch of a button.

Sana is the first non-invasive bio-therapeutic device that provides lasting relief for chronic pain sufferers.



Sana works in just 16 minutes – inducing deep relaxation and promoting hemispheric balance, which leads to relief of pain.

It can be used anywhere, anytime.



That’s why I developed the Sana device and why I’ve been pain free since 1993.
— Richard Hanbury, Inventor


After curing his own chronic pain in 1993, Richard Hanbury spent 24 years developing, testing and refining the Sana device.


Over 1,300 tests helped Sana's medical engineers create the optimum algorithms to effectively treat varying levels of pain intensity.

Learn more about the technology


Curing chronic pain, and other severe diseases.

Our team is comprised of a range of experts in biotechnology, bio-sensor wearables, pharmaceuticals, and consumer products. Our team have led major organisations such as AstraZeneca, Nasa, AcelRx, and McKinsey. We are also backed by world class expert advisors in sleep, pain and performance. 

Learn more about our growing team